Mr. Li has served as a member of our board of directors since June 2025. Mr. Li has served as Co-Founder and Managing Partner of Dimension Capital, a multistage investment firm at the interface of technology and life science, since April 2022. Dimension Capital partners with visionary founders working across therapeutics, diagnostics, software applications, automation systems and tech-enabled services. Mr. Li is interested in the development of cutting-edge technologies including computer vision, AI/ML, NLP, robotics and automation systems. Prior to founding Dimension Capital, Mr. Li was a Managing Director at Obvious Ventures from March 2015 to April 2022, where he worked with companies developing frontier technologies from early company formation through public markets. This includes Automata Technologies, Aspect Biosystems Ltd., Dexterity, Inc., Dyno Therapeutics, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, Planet Labs PBC (NYSE: PL), Recursion Pharmaceuticals (Nasdaq: RXRX) and SwiftScale Biologics. Mr. Li currently serves on the boards of directors of Aspect Biosystems Ltd., Automata Technologies, Fiveonefour Labs Inc. and Tamarind Bio, Inc. In addition, Mr. Li previously served on the boards of directors of Anagenix Ltd., Darwin Inc., Dexterity, Inc., Gandeeva Therapeutics, Inc., Inato, Inc., Iterative Scopes, Inc. d/b/a Iterative Health, LabGenius Therapeutics, Octave Health Group Inc. and The Aifleet Inc. Mr. Li holds a BSE in Computer Science from the University of Michigan. He has also been a lecturer at Stanford University on artificial intelligence and venture capital.
What is Nan Li's net worth?
The estimated net worth of Nan Li is at least $89.90 million as of May 11th, 2026. Mr. Li owns 3,333,516 shares of Odyssey Therapeutics stock worth more than $89,904,927 as of September 8th. This net worth approximation does not reflect any other investments that Mr. Li may own. Learn More about Nan Li's net worth.
Has Nan Li been buying or selling shares of Odyssey Therapeutics?
Nan Li has not been actively trading shares of Odyssey Therapeutics within the last three months. Most recently, on Monday, May 11th, Nan Li bought 1,111,111 shares of Odyssey Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director now directly owns 3,333,516 shares of the company's stock, valued at $60,003,288. Learn More on Nan Li's trading history.
Who are Odyssey Therapeutics' active insiders?
Are insiders buying or selling shares of Odyssey Therapeutics?
During the last year, Odyssey Therapeutics insiders bought shares 7 times. They purchased a total of 4,183,777 shares worth more than $75,319,986.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,780 shares worth more than $32,040.00. The most recent insider tranaction occured on May, 11th when Director
Nan Li bought 1,111,111 shares worth more than $19,999,998.00.
Learn More about insider trades at Odyssey Therapeutics. Information on this page was last updated on 5/11/2026.
